The U.S. Food and Drug Administration has extended its review timeline for Sanofi’s investigational type 1 diabetes therapy, Tzield, by more than one month, shifting the target decision date to March 20. This delay follows reports of three seizure events and one treatment-related fatality in the pivotal Phase 3 PROTECT-T1D study, which enrolled 512 patients. FDA reviewers have requested additional safety data on central nervous system effects and detailed post-adverse event monitoring protocols. Investors should note that Tzield represents a potential $1.8 billion annual market opportunity in the U.S., and this postponement increases regulatory uncertainty and may compress Sanofi’s projected 2026 revenue growth by up to 2 percentage points in its diabetes portfolio.

On January 15, China’s National Medical Products Administration approved Sanofi-licensed Myqorzo (aficamten) for obstructive hypertrophic cardiomyopathy (oHCM) and Redemplo (plozasiran) for familial chylomicronemia syndrome (FCS). The Myqorzo approval is based on the SEQUOIA-HCM Phase 3 trial (NCT05186818) in 386 symptomatic oHCM patients, which demonstrated a 45% mean increase in peak exercise capacity and a 60% reduction in New York Heart Association class III/IV symptoms at 24 weeks versus placebo. Redemplo’s approval follows the PALISADE Phase 3 study (NCT05089084) in 94 genetically confirmed FCS subjects, with median triglyceride reductions of 78% at 12 weeks. These launches reinforce Sanofi’s ambition to penetrate Greater China’s $2 billion cardiovascular and rare disease markets and support the company’s 15% annual growth target in emerging markets.

Chief Executive Officer Paul Hudson cautioned that U.S. vaccine uptake may see a slight decline in 2026, attributing the trend to widespread misinformation and intensified regulatory scrutiny. Sanofi expects annual influenza vaccine shipments to U.S. providers to contract by roughly 5% year-over-year, from 50 million doses to about 47.5 million. The company is countering this with targeted public education campaigns and streamlined manufacturing processes at its Swiftwater, Pennsylvania facility, where planned capacity expansions aim to boost output by 10% for the 2027 season. While the immediate impact may shave 0.3 percentage points off full-year revenue growth, management remains confident in achieving its mid-single-digit top-line targets through diversification in travel and pediatric vaccine segments.